Cargando…

Therapeutic approaches for non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have been reported as a novel worldwide epidemic, very often associated with obesity, metabolic syndrome, and type 2 diabetes. Both conditions have also been shown to be associated with a number of endocrine pathologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Gaal, Luc F., Mertens, Jonathan, Francque, Sven, De Block, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419532/ https://www.ncbi.nlm.nih.gov/pubmed/34497708 http://dx.doi.org/10.1177/20420188211034300

Ejemplares similares

NAFLD in type 1 diabetes: overrated or underappreciated?
por: Mertens, Jonathan, et al.
Publicado: (2021)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
por: Verlinden, Wim, et al.
Publicado: (2020)

Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy
por: Mertens, Jonathan, et al.
Publicado: (2021)

Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features
por: Vonghia, Luisa, et al.
Publicado: (2015)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα
por: Liang, Ning, et al.
Publicado: (2019)

Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes
por: Mertens, Jonathan, et al.
Publicado: (2023)

Predicting type 2 diabetes mellitus: a comparison between the FINDRISC score and the metabolic syndrome
por: Meijnikman, Abraham S., et al.
Publicado: (2018)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
por: Francque, Sven, et al.
Publicado: (2019)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic
por: Mouzaki, Marialena, et al.
Publicado: (2012)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis
por: Kim, Jimin, et al.
Publicado: (2021)

Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2018)

Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2020)

Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
por: Luci, Carmelo, et al.
Publicado: (2020)

Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease
por: Vonghia, Luisa, et al.
Publicado: (2019)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
por: Habig, Gregory, et al.
Publicado: (2021)

Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome
por: Ramalho, F. N., et al.
Publicado: (2017)

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma
por: Kumar, Rahul, et al.
Publicado: (2020)

Conophylline inhibits non-alcoholic steatohepatitis in mice
por: Nakade, Yukiomi, et al.
Publicado: (2017)

Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis
por: Cook, Nigel, et al.
Publicado: (2020)

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
por: Hartmann, Phillipp, et al.
Publicado: (2022)

CD4+RORγt++ and Tregs in a Mouse Model of Diet-Induced Nonalcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2015)

Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice
por: Willebrords, Joost, et al.
Publicado: (2017)

Identification of Autophagy-Related Genes in the Progression from Non-Alcoholic Fatty Liver to Non-Alcoholic Steatohepatitis
por: Ma, Mengyao, et al.
Publicado: (2021)

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
por: Brennan, Paul N, et al.
Publicado: (2022)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
por: Rios, Rafael S., et al.
Publicado: (2021)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Endothelial dysfunction in patients with non-alcoholic steatohepatitis
por: Onal, Ibrahim Koral
Publicado: (2014)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Mechanisms of ductular reaction in non-alcoholic steatohepatitis
por: Chen, Yue, et al.
Publicado: (2022)

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
por: Branković, Marija, et al.
Publicado: (2022)

Incidental finding of non-alcoholic steatohepatitis-cirrhosis
por: Adrian, Therese, et al.
Publicado: (2022)

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2961pnf3n2jsa5iusnp43fef67